A Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole CEP of the European Pharmacopoeia monograph is often referred to as a Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole Certificate of Suitability (COS). The purpose of a Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole to their clients by showing that a Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole CEP has been issued for it. The manufacturer submits a Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole CEP holder for the record. Additionally, the data presented in the Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole DMF.
A Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole suppliers with CEP (COS) on PharmaCompass.